search:cd133 antibody abcam相關網頁資料

瀏覽:615
日期:2024-04-16
Top of page Abstract Metastatic hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. However, the cell population responsible for its metastasis remains largely unknown. Here, we reported that CD133 + CD44 +/high defined a subgroup ...
瀏覽:442
日期:2024-04-16
Fujii et al. BMC Gastroenterology 2010, 10:79 http://www.biomedcentral.com/1471-230X/10/79 Page 4 of 11 then incubated with appropriate secondary antibodies for 1 h at room temperature. An antibody directed against β-actin (Abcam) was used to verify equal...
瀏覽:1394
日期:2024-04-18
Fig. 1. Enrichment of the prostate CSC-like population under sphere-forming conditions. (A) Flow cytometry analysis showed significant enrichment of the CD133 + /CD44 + population under sphere-forming conditions compared with monolayer conditions for DU14...
瀏覽:648
日期:2024-04-13
a, Representative magnetic resonance imaging (MRI) images from mice that received injection of DN, CD133 + /CD144 − or DP cells from primary GBM specimens. T2 sequences demonstrate infiltrative tumours except in the DN group. Tumours were hypercellular .....
瀏覽:1227
日期:2024-04-15
Identification of resident LSEC LRCs and progenitors. The LSEC expresses both CD31 and CD45 (8, 9). CD133 is a progenitor cell marker, and infusion of CD133 + cells from the BM repopulates the liver endothelium (8). We therefore used CD133 + CD45 + CD31 +...
瀏覽:659
日期:2024-04-13
Nevertheless, although this in vivo selection technique has provided new insight into the cellular and molecular mechanisms that control site-specific metastasis, there are some disadvantages. Perhaps the principal drawback of in vivo selection is that it...
瀏覽:1103
日期:2024-04-18
Complete information for PROM1 gene (protein-coding), prominin 1, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium ... Function for PROM1 gene (According to 1 UniProtKB, Genatlas, LifeMap...
瀏覽:796
日期:2024-04-13
INTRODUCTION Ovarian cancer is the leading cause of death due to gynecological cancer [1]. Recurrence and chemoresistance are the major burdens in the treatment of ovarian cancer. Increasing evidence have shown that a small subset of cells, termed cancer ...